Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 20/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19510779 | 0.86 | FFAR4 (0.47) | FFAR4 | |
| SCHEMBL24126006 | 0.86 | ALDH1A1 (0.43) | FFAR4 | |
| SCHEMBL19511268 | 0.84 | FFAR4 (0.48) | FFAR4 | |
| SCHEMBL25172775 | 0.84 | FFAR4 (0.45) | FFAR4 | |
| SCHEMBL30112371 | 0.83 | OPRK1 (0.41) | FFAR4 | |
| SCHEMBL29197661 | 0.83 | OPRK1 (0.41) | FFAR4 | |
| SCHEMBL24124684 | 0.81 | GAA (0.43) | FFAR4 | |
| SCHEMBL31334434 | 0.80 | ACHE (0.43) | FFAR4 | |
| SCHEMBL31333235 | 0.80 | HRH3 (0.39) | FFAR4 | |
| SCHEMBL31640106 | 0.80 | DPP4 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4168407-A1 | BRAF DEGRADERS | C4 Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2021127561-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | FFAR4 1147/4885 |
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | FFAR4 2485/4885 |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | FFAR4 3950/4885 |
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | FFAR4 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.